H.C. Wainwright raised the firm’s price target on Elicio Therapeutics to $11 from $10 and keeps a Buy rating on the shares. The analyst says ELI-002 2P clinical data appears promising. The firm looks forward to the initial ELI-002 7P results in the first half of 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELTX:
- Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
- Elicio announces first patient dosed in Phase 2 study of ELI-002
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
- Angion Biomedica Corp trading resumes
- Angion Biomedica Corp trading halted, volatility trading pause
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue